RC I001
Alternative Names: RC-I001U; RCI-001Latest Information Update: 27 Aug 2025
At a glance
- Originator Rudacure
- Developer Hanlim Pharmaceutical; Rudacure
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Rac1 GTP binding protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dry eyes
- Preclinical Corneal ulcer
Most Recent Events
- 20 Aug 2025 RudaCure plans phase II trial for Dry eyes in USA (Ophthalmic, solution) in 2026-2027 (RudaCure pipeline, August 2025)
- 20 Aug 2025 RudaCure plans phase II trial for corneal ulcers in South Korea (Ophthalmic, solution) in 2026-2027 (Ophthalmic, solution) (RudaCure pipeline, August 2025)
- 16 Jul 2025 Ora Inc plans a phase II trial for Dry Eyes (Ophthalmic, Solution), in August 2025 (NCT07068958)